Perceptive Advisors LLC Macrogenics Inc Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $2.28 Million - $5.02 Million	-233,605 Reduced 38.17%	378,327 $5.57 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $2.74 Million - $6.19 Million	611,932 New	611,932 $5.89 Million
Q2 2022 Aug 15, 2022	SELL	$2.25 - $9.99 $748,320 - $3.32 Million	-332,587 Reduced 21.32%	1,227,202 $3.62 Million
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $856,286 - $1.78 Million	-105,454 Reduced 6.33%	1,559,789 $13.7 Million
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $7.68 Million - $10.6 Million	-482,817 Reduced 22.48%	1,665,243 $26.7 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $16.8 Million - $29.4 Million	887,000 Added 70.34%	2,148,060 $68.4 Million
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $584,648 - $783,146	-30,121 Reduced 2.33%	1,261,060 $28.8 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $78,193 - $100,077	3,167 Added 0.25%	1,291,181 $32.5 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $6.7 Million - $37.5 Million	1,288,014 New	1,288,014 $36 Million

131

56M

28.3K

197K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $128M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.